skip banner navigation
National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI

Clinical Trial Results

Summaries of Newsworthy Clinical Trial Results


Page Options
Print This Page  Print This Page
E-Mail This Document  E-Mail This Document
Search by Cancer Type
Breast Cancer

Lung Cancer

Prostate Cancer

More Results
Search Results

    Go  
Quick Links
Dictionary
Cancer-related terms

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

NCI Calendar
Scientific meetings

Español
Informacion en español
NCI Highlights
Chemo Extends Life in Advanced Prostate Cancer

Temozolomide Plus Radiation Helps Brain Cancer

Confirmed: Raloxifene Drops Risk of Breast Cancer

Bortezomib Delays Progression of Multiple Myeloma

Annual Report to the Nation

Past Highlights
Need Help?
Related Pages
Search for Clinical Trials
NCI's PDQ® database of cancer clinical trials.

Featured Clinical Trials Supported by NCI
A weekly update of noteworthy NCI cancer trials you can join.

Search Cancer Literature in PubMed
PubMed, a service of the National Library of Medicine, provides access to more than 12 million MEDLINE citations.
Clinical Trial Results - Progress in Cancer Care

These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.

The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.

1.  Study Shows Strong Tobacco Control Programs and Policies Can Lower Smoking Rates
(Posted: 11/18/2003, Updated: 06/16/2004) - A study published today in the Journal of the National Cancer Institute provides the latest evidence that investing in state tobacco control programs can reduce smoking rates.

2.  Bevacizumab (Avastin™) Improves Survival in Metastatic Colorectal Cancer
(Posted: 06/01/2003, Updated: 06/14/2004) - Patients with newly diagnosed metastatic colon cancer who received the therapeutic agent bevacizumab (Avastin™) along with the chemotherapy combination known as IFL had substantially longer overall survival times than patients who received IFL but with a placebo instead of bevacizumab. With these results, bevacizumab becomes the first anti-angiogenesis agent to prove effective in a randomized Phase III trial.

3.  Limited Lymph Node Removal and Stomach Cancer
(Posted: 05/05/2004, Updated: 06/14/2004) - In a Dutch study, patients with stomach (gastric) cancer who were treated with more extensive surgery involving the removal of more lymph nodes did not live longer than those who received a more limited lymph node removal (dissection). The study was published online April 13, 2004, by the Journal of Clinical Oncology.

4.  Oxaliplatin-Based Regimen Prolongs Survival After Colorectal Cancer Surgery
(Posted: 06/01/2003, Updated: 06/14/2004) - The oxaliplatin-based chemotherapy combination known as FOLFOX significantly improved disease-free survival compared to 5-FU and leucovorin when used as adjuvant therapy (after surgery) in patients with stage II and stage III colorectal cancer.

5.  Zoledronic Acid Reduces Bone Complications of Advanced Prostate Cancer
(Posted: 06/21/2002, Updated: 06/14/2004) - In a study published in the October 2, 2002, issue of the Journal of the National Cancer Institute, patients with prostate cancer that had spread to the bones had fewer fractures and other bone complications when they took a new drug, zoledronic acid (also called zolendronate or Zometa®) than when they took a placebo.
1 2 3 4   Next >
skip footer navigation

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health FirstGov.gov